Surrozen, Inc./DE

Consonance-HFW Acquisition Corp (Nasdaq: CHFW), sponsored by Consonance Capital Management in partnership with HFW, was a blank check company focused on the biotech and pharmaceutical sector that completed its business combination with Surrozen, Inc., a Delaware-incorporated clinical-stage biopharmaceutical company developing Wnt pathway modulators for tissue repair and regeneration. CHFW went public in 2021 and announced the Surrozen transaction in April of that year. The deal is now closed, with Surrozen continuing as a publicly traded company following the completed de-SPAC process. Sign up at SpacDesk for full data on CHFW, Surrozen, sponsor backgrounds, and thousands of other SPAC transactions.

SPAC Counterparty (1)